Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib vs Physician's Choice in Myelofibrosis with Severe Thrombocytopenia (PACIFICA)
NCT03165734Phase 3Active, not recruiting
- Sponsor
- Sobi
- Start
- Jun 2017
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of pacritinib in myelofibrosis (MF) (2 arms), sponsored by Sobi. Primary endpoints: Spleen volume at 24 weeks and Total Symptom Score at 24 weeks. Started Jun 2017; status: active, not recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03165734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165734.